FATE
Fate Therapeutics Inc
NASDAQ: FATE · HEALTHCARE · BIOTECHNOLOGY
$1.25
+0.81% today
Updated 2026-04-30
Market cap
$154.63M
P/E ratio
—
P/S ratio
23.27x
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Fate Therapeutics Inc (FATE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-2,456.00%
ROE
-51.80%
ROA
-24.10%
Debt/equity
0.34x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $1.17M | $-13.43M | 100.00% | -1,136.15% | -1,147.61% |
| 2012 | $2.67M | $-14.24M | -349.40% | -507.75% | -533.30% |
| 2013 | $971000.00 | $-20.89M | -1,136.56% | -1,820.29% | -2,151.80% |
| 2014 | $0.00 | $-25.88M | — | — | — |
| 2015 | $2.43M | $-29.99M | -716.99% | -1,142.82% | -1,233.73% |
| 2016 | $4.40M | $-33.46M | -500.91% | -726.10% | -760.15% |
| 2017 | $4.11M | $-42.95M | -736.78% | -1,025.94% | -1,046.08% |
| 2018 | $4.74M | $-66.60M | -1,081.94% | -1,415.44% | -1,405.02% |
| 2019 | $10.68M | $-98.15M | 100.00% | -943.14% | -919.00% |
| 2020 | $31.43M | $-173.39M | -299.64% | -407.47% | -551.59% |
| 2021 | $55.85M | $-212.15M | 89.52% | -388.56% | -379.89% |
| 2022 | $96.30M | $-255.06M | 100.00% | -320.23% | -264.86% |
| 2023 | $63.53M | $-160.93M | -147.41% | -299.86% | -253.30% |
| 2024 | $13.63M | $-186.26M | 100.00% | -1,542.63% | -1,366.46% |
| 2025 | $6.65M | $-136.31M | -94.12% | -2,222.45% | -2,051.08% |